Real-time enrollment status for this acute myeloid leukemia, in relapse clinical trial
Current Status
Recruiting
Checked: October 15, 2026 at 5:12 AM UTC
| NCT Number | NCT06552416 |
| Recruiting Status | Recruiting |
| Condition | Acute Myeloid Leukemia, in Relapse |
| Phase | PHASE1 |
| Target Enrollment | 40 participants |
| Active Locations | 3 sites in the US |
| Sponsor | Marker Therapeutics, Inc. |
| Last Updated on CT.gov | December 16, 2025 (Dec 16, 2025) |
As of October 15, 2026: Clinical trial NCT06552416 is currently recruiting participants. This phase1 study for acute myeloid leukemia, in relapse is actively seeking new participants at 3 locations across the United States. The study is sponsored by Marker Therapeutics, Inc.. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT06552416 is actively recruiting participants as of October 15, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 3 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT06552416 was last updated Dec 16, 2025 (December 16, 2025). HelloStudys verifies this status automatically.